Advances in diagnostics for transplant rejection.
Advances in diagnostics for transplant rejection.
复制标题
DOI：
10.1080/14737159.2016.1239530
复制
发表时间：
2016-10
影响因子：
5.1
通讯作者：
Sarwal M
中科院分区：
文献类型：
--
作者：
Nasr M;Sigdel T;Sarwal M
识别同种异体移植物损伤，包括急性临床和亚临床损伤，对于延长移植器官的寿命至关重要。由于多种免疫和非免疫因素（包括免疫细胞和针对供体特异性表位的抗体的浸润）而发生的急性排斥对器官构成显著风险。近年来，在分子诊断中发现了新的基因组、转录组和蛋白质组生物标志物，这些生物标志物通过提供排斥反应事件的早期检测，为移植器官的个性化管理提供了更好的潜力。本综述是通过对与该领域相关的全文出版物以及参考文献列表和综述文章中的相关文章进行关键词检索而编制的。最近在同种异体移植物损伤的分子诊断方面的许多进展显示出很大的希望，但在它们完全实现之前，必须进行更大样本集的进一步验证。此外，为了更好地了解治疗决策，必须完成更多的工作来区分不同的损伤原因。此外，诊断领域正在寻找允许多重化的方法，同时识别多个目标的能力，以提供更强大的生物标志物和更好的理解。
Identification of allograft injury, including acute clinical and subclinical injury, is vital in increasing the longevity of the transplanted organ. Acute rejection, which occurs as a result of a variety of immune and non-immune factors including the infiltration of immune cells and antibodies to the donor specific epitopes, poses a significant risk to the organ. Recent years have marked an increase in the discovery of new genomic, transcriptomic, and proteomic biomarkers in molecular diagnostics, which offer better potential for personalized management of the transplanted organ by providing earlier detection of rejection episodes. This review was compiled from key word searches of full-text publications relevant to the field as well as relevant articles from reference lists and review articles. Many of the recent advancements in the molecular diagnostics of allograft injury show much promise, but before they can be fully realized further validation in larger sample sets must be conducted. Additionally, for better informed therapeutic decisions, more work must be completed to differentiate between different causes of injury. Moreover, the diagnostics field is looking at methodologies that allow for multiplexing, the ability to identify multiple targets simultaneously, in order to provide more robust biomarkers and better understanding.